In_IN Vitro_NP Interaction_NP of_IN Flucytosine_NP Combined_NP with_IN Amphotericin_NP B_NP or_CC Fluconazole_NP against_IN Thirty-Five_NP Yeast_NP Isolates_NP Determined_NP by_IN both_CC the_DT Fractional_NP Inhibitory_NP Concentration_NP Index_NP and_CC the_DT Response_NP Surface_NP Approach_NP Combination_NP therapy_NN could_MD be_VB of_IN benefit_NN for_IN the_DT treatment_NN of_IN invasive_JJ yeast_NN infections_NNS ._SENT However_RB ,_, in_IN vitro_NN interaction_NN studies_NNS are_VBP relatively_RB scarce_JJ and_CC the_DT interpretation_NN of_IN the_DT fractional_JJ inhibitory_JJ concentration_NN (_( FIC_NP )_) index_NN can_MD be_VB contradictory_JJ due_RB to_TO various_JJ definitions_NNS used_VBN ;_: not_RB all_DT information_NN on_IN the_DT interaction_NN study_NN is_VBZ used_VBN in_IN the_DT index_NN ,_, and_CC different_JJ MIC_JJ end_NN points_NNS exist_VBP for_IN different_JJ classes_NNS of_IN drugs_NNS ._SENT Fitting_VBG an_DT interaction_NN model_NN to_TO the_DT whole_JJ response_NN surface_NN and_CC estimation_NN of_IN an_DT interaction_NN coefficient_NN alpha_NN (_( ICalpha_NP )_) would_MD overcome_VB these_DT objections_NNS and_CC has_VBZ the_DT additional_JJ advantage_NN that_IN confidence_NN intervals_NNS of_IN the_DT interaction_NN are_VBP obtained_VBN ._SENT The_DT efficacy_NN of_IN flucytosine_NN (_( 5FC_NN )_) in_IN combination_NN with_IN amphotericin_NP B_NP (_( AB_NP )_) and_CC fluconazole_NP (_( FCZ_NP )_) was_VBD studied_VBN against_IN 35_CD yeast_NN isolates_NNS in_IN triplicate_NN (_( Candida_NP albicans_NP [_SYM n_NN =_SYM 9_CD ]_SYM ,_, Candida_NP glabrata_NP [_SYM n_NN =_SYM 9_CD ]_SYM ,_, Candida_NP krusei_NP [_SYM n_NN =_SYM 9_CD ]_SYM ,_, and_CC Cryptococcus_NP neoformans_NP [_SYM n_NN =_SYM 8_CD ]_SYM )_) using_VBG a_DT broth_NN microdilution_NN checkerboard_NN method_NN and_CC measuring_VBG growth_NN after_IN 48_CD h_NN by_IN a_DT spectrophotometer_NN ._SENT The_DT FIC_JJ index_NN and_CC ICalpha_NP were_VBD determined_VBN ,_, the_DT latter_NN by_IN estimation_NN from_IN the_DT response_NN surface_NN approach_NN described_VBN by_IN Greco_NP et_FW al._FW (_( W._NP R._NP Greco_NP ,_, G._NP Bravo_NP ,_, and_CC J._NP C._NP Parsons_NP ,_, Pharmacol_NP ._SENT Rev._NP 47:331-385_CD ,_, 1995_CD )_) by_IN using_VBG a_DT computer_NN program_NN developed_VBN for_IN that_DT purpose_NN ._SENT For_IN the_DT 5FC-FCZ_NP combination_NN ,_, the_DT interactions_NNS determined_VBN by_IN the_DT ICalpha_NP generally_RB were_VBD in_IN concordance_NN with_IN the_DT interactions_NNS determined_VBN by_IN the_DT FIC_JJ index_NN ,_, but_CC large_JJ discrepancies_NNS were_VBD found_VBN between_IN both_DT methods_NNS for_IN the_DT 5FC-AB_JJ combination_NN ._SENT These_DT could_MD mainly_RB be_VB explained_VBN by_IN shortcomings_NNS in_IN the_DT FIC_JJ approach_NN ._SENT The_DT in_IN vitro_NN interaction_NN of_IN 5FC-AB_NP demonstrated_VBD variable_JJ results_NNS depending_VBG on_IN the_DT tested_VBN Candida_NP isolate_NN ._SENT In_IN general_NN ,_, the_DT 5FC-FCZ_NP combination_NN was_VBD antagonistic_JJ against_IN Candida_NP species_NNS ,_, but_CC for_IN some_DT Candida_NP isolates_NNS synergism_NN was_VBD found_VBN ._SENT For_IN C._NP neoformans_NNS the_DT interaction_NN for_IN both_DT combinations_NNS was_VBD highly_RB dependent_JJ on_IN the_DT tested_VBN isolate_NN and_CC the_DT method_NN used_VBD ._SENT Response_NN surface_NN approach_NN is_VBZ an_DT alternative_JJ method_NN for_IN determining_VBG the_DT interaction_NN between_IN antifungal_JJ agents_NNS ._SENT By_IN using_VBG this_DT approach_NN ,_, some_DT of_IN the_DT problems_NNS encountered_VBN with_IN the_DT FIC_NP were_VBD overcome_VBN ._SENT Opportunistic_JJ yeast_NN infections_NNS ,_, such_JJ as_IN candidiasis_NN and_CC cryptococcosis_NN ,_, occur_VBP particularly_RB in_IN immunocompromised_JJ patients_NNS ,_, such_JJ as_IN cancer_NN patients_NNS and_CC transplant_NN recipients_NNS ._SENT The_DT treatment_NN of_IN these_DT infections_NNS is_VBZ still_RB problematic_JJ ._SENT Only_RB a_DT few_JJ antifungal_JJ agents_NNS are_VBP currently_RB available_JJ ,_, and_CC although_IN therapeutic_JJ options_NNS have_VBP increased_VBN considerably_RB during_IN the_DT last_JJ decade_NN due_JJ to_TO the_DT introduction_NN of_IN new_JJ agents_NNS ,_, efficacy_NN is_VBZ not_RB always_RB optimal_JJ ._SENT Several_JJ drugs_NNS cause_VBP toxicity_NN ,_, and_CC resistance_NN to_TO new_JJ agents_NNS is_VBZ on_IN the_DT rise_NN ._SENT One_CD way_NN to_TO enhance_VB treatment_NN is_VBZ to_TO combine_VB antifungal_JJ agents_NNS ._SENT Antifungal_JJ agents_NNS given_VBN in_IN combination_NN may_MD improve_VB efficacy_NN due_JJ to_TO synergism_NN ,_, and_CC because_IN the_DT dose_NN can_MD possibly_RB be_VB lowered_VBN ,_, side_NN effects_NNS could_MD be_VB reduced_VBN ._SENT Another_DT advantage_NN of_IN combination_NN therapy_NN is_VBZ the_DT reduction_NN of_IN the_DT development_NN of_IN resistance_NN and_CC possibly_RB a_DT shorter_JJR duration_NN of_IN therapy_NN ._SENT Flucytosine_NP (_( 5FC_NP )_) is_VBZ a_DT drug_NN with_IN a_DT limited_JJ spectrum_NN of_IN action_NN that_WDT includes_VBZ Candida_NP spp._NP and_CC Cryptococcus_NP neoformans_NNS ._SENT Because_IN resistance_NN to_TO 5FC_NN emerges_VBZ relatively_RB fast_RB ,_, the_DT drug_NN is_VBZ preferably_RB given_VBN in_IN combination_NN with_IN other_JJ antifungal_JJ agents_NNS ._SENT Although_IN 5FC_NP has_VBZ been_VBN given_VBN in_IN combination_NN with_IN other_JJ agents_NNS and_CC has_VBZ been_VBN evaluated_VBN in_IN several_JJ clinical_JJ trials_NNS ,_, little_RB is_VBZ known_VBN of_IN the_DT in_IN vitro_NN interaction_NN of_IN 5FC_NN with_IN other_JJ drugs_NNS ._SENT The_DT fractional_JJ inhibitory_JJ concentration_NN (_( FIC_NP )_) index_NN is_VBZ the_DT most_RBS frequently_RB used_VBN analysis_NN to_TO quantify_VB drug_NN interaction_NN ._SENT Despite_IN the_DT fact_NN that_IN this_DT method_NN has_VBZ some_DT important_JJ disadvantages_NNS ,_, it_PP is_VBZ widely_RB used_VBN ._SENT The_DT first_JJ disadvantage_NN is_VBZ that_IN one_CD index_NN (_( the_DT FIC_JJ index_NN )_) is_VBZ used_VBN for_IN many_JJ results_NNS :_: the_DT result_NN of_IN every_DT well_NN in_IN the_DT checkerboard_NN is_VBZ confined_VBN in_IN one_CD index_NN ,_, while_IN there_EX may_MD be_VB more_JJR refinement_NN necessary_JJ since_IN at_IN some_DT concentrations_NNS there_EX may_MD be_VB synergism_NN but_CC for_IN others_NNS there_EX may_MD be_VB indifference_NN or_CC even_RB antagonism_NN ._SENT Another_DT disadvantage_NN is_VBZ that_IN for_IN some_DT antifungal_JJ combinations_NNS it_PP is_VBZ not_RB clear_JJ at_IN which_WDT MIC_JJ end_NN point_NN the_DT combination_NN should_MD be_VB read_VBN and_CC ,_, thus_RB ,_, how_WRB to_TO determine_VB the_DT FIC_JJ index_NN ._SENT For_IN amphotericin_NP B_NP (_( AB_NP )_) and_CC most_JJS antibacterial_NN agents_NNS ,_, end_NN points_NNS are_VBP easily_RB defined_VBN (_( one_CD dilution_NN )_) and_CC the_DT MIC_NN is_VBZ read_VBN as_IN the_DT lowest_JJS drug_NN concentration_NN that_WDT showed_VBD 100_CD %_NN growth_NN inhibition_NN (_( MIC-0_NP )_) ._SENT For_IN 5FC_NN and_CC especially_RB for_IN azoles_NNS ,_, end_NN points_NNS are_VBP less_RBR sharp_JJ (_( range_NN of_IN twofold_JJ dilutions_NNS )_) and_CC exhibit_VB a_DT trailing_VBG growth_NN effect_NN ._SENT The_DT MIC_NN is_VBZ read_VBN as_IN the_DT lowest_JJS drug_NN concentration_NN that_WDT showed_VBD 50_CD %_NN or_CC more_JJR growth_NN inhibition_NN (_( MIC-2_NP )_) ._SENT When_WRB AB_NP is_VBZ combined_VBN with_IN 5FC_NP or_CC an_DT azole_NN ,_, the_DT combination_NN can_MD be_VB read_VBN at_IN either_DT MIC-0_NP or_CC at_IN MIC-2_NP ._SENT Finally_RB ,_, a_DT third_JJ disadvantage_NN is_VBZ that_IN there_EX are_VBP several_JJ different_JJ definitions_NNS described_VBN in_IN the_DT literature_NN for_IN the_DT interpretation_NN of_IN the_DT FIC_JJ index_NN ,_, and_CC it_PP is_VBZ still_RB not_RB clear_VB which_WDT of_IN these_DT definitions_NNS should_MD be_VB used_VBN ._SENT To_TO overcome_VB these_DT problems_NNS alternative_NN methods_NNS have_VBP been_VBN sought_VBN for_IN and_CC developed_VBN ,_, especially_RB in_IN the_DT area_NN of_IN antiviral_JJ drugs_NNS ._SENT Instead_RB of_IN the_DT reading_NN of_IN a_DT single_JJ well_RB (_( the_DT MIC_NP )_) ,_, the_DT whole_JJ response_NN surface_NN is_VBZ taken_VBN into_IN account_NN ._SENT By_IN fitting_VBG a_DT model_NN to_TO the_DT whole_JJ response_NN surface_NN ,_, an_DT objective_JJ criterion_NN for_IN the_DT interaction_NN is_VBZ obtained_VBN ._SENT The_DT interaction_NN can_MD be_VB further_RBR characterized_VBN by_IN statistical_JJ analysis_NN and_CC confidence_NN intervals_NNS ._SENT One_CD of_IN the_DT models_NNS based_VBN on_IN the_DT response_NN surface_NN approach_NN is_VBZ the_DT fully_RB parametric_JJ model_NN described_VBN by_IN Greco_NP et_FW al._FW which_WDT is_VBZ an_DT Emax-based_JJ model_NN (_( Emax_NP model_NN or_CC Hill_NP equation_NN with_IN variable_JJ slope_NN )_) and_CC fits_VBZ to_TO the_DT entire_JJ data_NNS set_VBN with_IN a_DT nonlinear_JJ regression_NN analysis_NN ._SENT The_DT nature_NN and_CC the_DT intensity_NN of_IN an_DT interaction_NN are_VBP summarized_VBN with_IN a_DT nonunit_NN ,_, concentration-independent_JJ interaction_NN parameter_NN that_WDT includes_VBZ the_DT uncertainty_NN in_IN the_DT estimate_NN ._SENT We_PP developed_VBD a_DT program_NN ,_, called_VBD ModLab_NP ,_, which_WDT fits_VBZ the_DT Greco_NP model_NN to_TO the_DT whole_JJ response_NN surface_NN and_CC then_RB estimates_VBZ the_DT model_NN parameters_NNS ,_, including_VBG the_DT interaction_NN parameter_NN ,_, with_IN their_PP$ 95_CD %_NN confidence_NN intervals_NNS ._SENT The_DT aim_NN of_IN this_DT study_NN was_VBD to_TO investigate_VB the_DT in_IN vitro_NN interaction_NN of_IN 5FC_NN in_IN combination_NN with_IN AB_NP or_CC fluconazole_NP (_( FCZ_NP )_) against_IN a_DT collection_NN of_IN 35_CD clinical_JJ yeast_NN isolates_VBZ by_IN a_DT broth_NN microdilution_NN checkerboard_NN assay_NN ._SENT The_DT interaction_NN was_VBD determined_VBN using_VBG both_CC the_DT FIC_JJ index_NN and_CC a_DT response_NN surface_NN approach_NN ._SENT (_( Part_NN of_IN these_DT results_NNS were_VBD presented_VBN at_IN the_DT 40th_JJ Interscience_NN Conference_NN on_IN Antimicrobial_JJ Agents_NNS and_CC Chemotherapy_NN ,_, Toronto_NP ,_, Canada_NP ,_, 2000_CD ._SENT )_) Test_NP isolates_VBZ ._SENT |_SYM Thirty-five_JJ clinical_JJ yeast_NN isolates_NNS were_VBD tested_VBN :_: Candida_NP albicans_NNS (_( n_NN =_SYM 9_CD )_) ,_, Candida_NP glabrata_NP (_( n_NN =_SYM 9_CD )_) ,_, Candida_NP krusei_NP (_( n_NN =_SYM 9_CD )_) ,_, and_CC Cryptococcus_NP neoformans_NP (_( n_NN =_SYM 8_CD )_) ._SENT The_DT isolates_NNS were_VBD part_NN of_IN the_DT private_JJ collection_NN of_IN the_DT Department_NP of_IN Medical_NP Microbiology_NP ,_, University_NP Medical_NP Center_NP Nijmegen_NP ,_, Nijmegen_NP ,_, The_DT Netherlands_NPS ._SENT The_DT isolates_NNS were_VBD grown_VBN on_IN Sabouraud_NP glucose_NN agar_NN at_IN 28C_JJ for_IN 24_CD to_TO 72_CD h._NN They_PP were_VBD subcultured_VBN again_RB on_IN Sabouraud_NP glucose_NN agar_NN for_IN 24_CD h_NN before_IN preparation_NN of_IN the_DT inoculum_NN ._SENT All_DT isolates_NNS were_VBD tested_VBN in_IN triplicate_NN on_IN different_JJ days_NNS ._SENT Candida_NP parapsilosis_NN (_( ATCC_NP 22019_CD )_) and_CC C._NP neoformans_NP (_( ATCC_NP 90112_CD )_) were_VBD used_VBN for_IN quality_NN control_NN in_IN all_DT experiments_NNS ._SENT Antifungal_JJ agents_NNS ._SENT |_SYM 5FC_NP (_( ICN_NP Pharmaceuticals_NP ,_, Zoetermeer_NP ,_, The_DT Netherlands_NPS )_) ,_, AB_NP (_( Bristol-Myers_NP Squibb_NP ,_, Woerden_NP ,_, The_DT Netherlands_NPS )_) ,_, and_CC FCZ_NP (_( Pfizer_NP ,_, Capelle_NP aan_NN den_NN IJssel_NP ,_, The_DT Netherlands_NPS )_) were_VBD obtained_VBN as_IN powders_NNS ._SENT 5FC_NP and_CC FCZ_NP were_VBD dissolved_VBN in_IN distilled_JJ water_NN and_CC AB_NP was_VBD dissolved_VBN in_IN dimethyl_NN sulfoxide_NN to_TO make_VB stock_NN solutions_NNS ._SENT The_DT stock_NN solutions_NNS were_VBD held_VBN at_IN -80C_NN until_IN use_NN ._SENT Serial_JJ twofold_JJ dilutions_NNS of_IN each_DT antifungal_JJ agent_NN were_VBD prepared_VBN following_VBG NCCLS_NP guidelines_NNS ._SENT Final_JJ dilutions_NNS were_VBD made_VBN in_IN RPMI_NP 1640_CD medium_NN (_( with_IN l-glutamine_NN ,_, without_IN bicarbonate_NN )_) (_( GIBCO_NP BRL_NP ,_, Life_NP Technologies_NPS ,_, Woerden_NP ,_, The_DT Netherlands_NPS )_) buffered_VBD to_TO pH_NN 7.0_CD with_IN morpholinepropanesulfonic_JJ acid_NN (_( MOPS_NP )_) (_( 0.165_CD mol/liter_NN ;_: Sigma-Aldrich_NP Chemie_NP GmbH_NP ,_, Steinheim_NP ,_, Germany_NP )_) ._SENT Interaction_NN of_IN drugs_NNS in_IN vitro_NN ._SENT |_SYM Drug_NP interactions_NNS were_VBD assessed_VBN by_IN a_DT broth_NN microdilution_NN checkerboard_NN method_NN ._SENT The_DT final_JJ concentrations_NNS of_IN the_DT antifungal_JJ agents_NNS ranged_VBN from_IN 0.004_CD to_TO 512_CD mug/ml_NN for_IN 5FC_NP ,_, 0.002_CD to_TO 2_CD mug/ml_NN for_IN AB_NP ,_, and_CC 0.008_CD to_TO 512_CD mug/ml_NN for_IN FCZ_NP ._SENT Aliquots_NNS of_IN 50_CD mul_NN of_IN each_DT drug_NN at_IN a_DT concentration_NN four_CD times_NNS the_DT targeted_JJ final_JJ concentration_NN were_VBD dispensed_VBN in_IN the_DT wells_NNS of_IN flat-bottom_NN 96-well_NN microtiter_NN plates_NNS (_( Costar_NP ,_, Corning_NP ,_, N.Y._NP )_) ._SENT Yeast_NN inocula_NNS were_VBD prepared_VBN spectrophotometrically_RB ,_, and_CC further_RBR diluted_JJ in_IN RPMI_NP 1640_CD medium_NN ._SENT In_IN order_NN to_TO obtain_VB a_DT final_JJ concentration_NN of_IN 0.5_CD to_TO 2.5_CD x_SYM 103_CD CFU/ml_NP ,_, 100_CD mul_NN of_IN the_DT yeast_NN suspension_NN was_VBD added_VBN to_TO each_DT well_NN ._SENT The_DT microtiter_NN plates_NNS were_VBD incubated_VBN at_IN 35C_JJ for_IN 48_CD h._JJ Readings_NPS were_VBD performed_VBN spectrophotometrically_RB with_IN a_DT microplate_NN reader_NN (_( Anthos_NP htIII_NP ;_: Anthos_NP Labtec_NP Instruments_NP ,_, Salzburg_NP ,_, Austria_NP )_) at_IN 405_CD nm_NN ._SENT The_DT optical_JJ densities_NNS (_( ODs_NN )_) of_IN the_DT blank_NN ,_, which_WDT consisted_VBD of_IN an_DT uninoculated_JJ plate_NN incubated_VBD together_RB with_IN the_DT inoculated_VBN plates_NNS ,_, were_VBD subtracted_VBN from_IN the_DT ODs_NN of_IN the_DT inoculated_VBN plates_NNS ._SENT The_DT percentage_NN of_IN growth_NN for_IN each_DT well_NN was_VBD calculated_VBN by_IN comparing_VBG the_DT OD_NN of_IN the_DT wells_NNS with_IN that_DT of_IN the_DT drug-free_JJ control_NN :_: (_( OD405_JJ of_IN wells_NNS that_WDT contained_VBD the_DT drug/OD405_NN of_IN the_DT drug-free_JJ well_RB )_) x_SYM 100_CD %_NN ._SENT The_DT MIC_NP of_IN AB_NP was_VBD defined_VBN as_IN the_DT lowest_JJS concentration_NN that_WDT inhibited_VBD growth_NN by_IN 100_CD %_NN compared_VBN with_IN that_DT of_IN the_DT drug-free_JJ well_RB (_( MIC-0_NP )_) ._SENT The_DT MICs_NP of_IN 5FC_NP and_CC FCZ_NP were_VBD defined_VBN as_IN the_DT lowest_JJS concentrations_NNS that_WDT inhibited_VBD growth_NN by_IN 80_CD %_NN or_CC more_RBR compared_VBN with_IN that_DT of_IN the_DT drug-free_JJ well_RB (_( MIC-1_NP )_) ._SENT For_IN the_DT 5FC-AB_JJ combination_NN MIC-0_NP was_VBD taken_VBN as_IN an_DT end_NN point_NN ,_, and_CC for_IN the_DT 5FC-FCZ_NP combination_NN MIC-1_NP was_VBD taken_VBN as_IN an_DT end_NN point_NN ._SENT Definitions_NNS ._SENT |_SYM Drug_NP interaction_NN was_VBD determined_VBN by_IN the_DT FIC_JJ index_NN and_CC by_IN the_DT interaction_NN coefficient_NN alpha_NN (_( ICalpha_NP )_) based_VBN on_IN the_DT response_NN surface_NN approach_NN by_IN Greco_NP et_FW al._FW ._SENT The_DT FIC_NP index_NN was_VBD defined_VBN as_RB follows_VBZ :_: The_DT interaction_NN was_VBD defined_VBN as_IN synergistic_JJ if_IN the_DT FIC_JJ index_NN was_VBD <1,_additive 1_CD ._SENT The_DT response_NN surface_NN approach_NN by_IN Greco_NP et_FW al._FW was_VBD described_VBN by_IN the_DT following_VBG equation_NN :_: where_WRB and_CC where_WRB D1_NP and_CC D2_NP are_VBP the_DT concentrations_NNS of_IN drugs_NNS 1_CD and_CC 2_CD ,_, IC50,1_NP and_CC IC50,2_NP are_VBP the_DT concentrations_NNS of_IN drug_NN 1_CD and_CC drug_NN 2_CD resulting_VBG in_IN 50_CD %_NN inhibition_NN ,_, E_NP is_VBZ the_DT measured_JJ response_NN ,_, Econ_NP is_VBZ the_DT control_NN response_NN ,_, m1_JJ and_CC m2_JJ are_VBP the_DT slope_NN parameters_NNS for_IN drug_NN 1_CD and_CC 2_CD in_IN a_DT constant_JJ ratio_NN ,_, and_CC alpha_NN is_VBZ the_DT synergism-antagonism_NN interaction_NN parameter_NN (_( ICalpha_NP )_) ._SENT This_DT model_NN was_VBD fitted_VBN directly_RB to_TO the_DT entire_JJ set_NN of_IN experimental_JJ data_NNS (_( percentages_NNS of_IN growth_NN for_IN all_DT concentrations_NNS of_IN the_DT two_CD drugs_NNS alone_RB or_CC in_IN combination_NN )_) with_IN a_DT nonweighted_JJ ,_, nonlinear_JJ regression_NN analysis_NN using_VBG a_DT computer_NN program_NN (_( ModLab_NP ;_: Medimatics_NP ,_, Maastricht_NP ,_, The_DT Netherlands_NPS )_) ._SENT The_DT program_NN estimated_VBD the_DT model_NN parameters_NNS ,_, and_CC it_PP also_RB calculated_VBD the_DT 95_CD %_NN confidence_NN interval_NN for_IN each_DT parameter_NN ._SENT Validation_NN of_IN obtained_VBN parameters_NNS was_VBD done_VBN using_VBG the_DT program_NN Syner_NN ,_, kindly_RB provided_VBN to_TO us_PP by_IN G._NP L._NP Drusano_NP ._SENT If_IN the_DT estimate_NN of_IN alpha_NN is_VBZ zero_CD ,_, the_DT combination_NN is_VBZ additive_JJ ._SENT If_IN it_PP is_VBZ positive_JJ ,_, the_DT interaction_NN is_VBZ synergistic_JJ ._SENT If_IN it_PP is_VBZ negative_JJ ,_, the_DT interaction_NN is_VBZ antagonistic_JJ ._SENT The_DT estimate_NN of_IN alpha_NN has_VBZ an_DT associated_VBN 95_CD %_NN confidence_NN interval_NN ._SENT If_IN the_DT confidence_NN interval_NN does_VBZ not_RB overlap_VB zero_NN ,_, this_DT provides_VBZ the_DT statistical_JJ significance_NN for_IN the_DT estimate_NN of_IN the_DT interaction_NN ._SENT That_DT is_VBZ ,_, if_IN the_DT 95_CD %_NN confidence_NN interval_NN crosses_NNS zero_VBP ,_, the_DT interaction_NN is_VBZ additive_JJ ._SENT If_IN it_PP does_VBZ not_RB and_CC alpha_NN is_VBZ positive_JJ ,_, the_DT interaction_NN is_VBZ significantly_RB synergistic_JJ ._SENT If_IN it_PP does_VBZ not_RB and_CC alpha_NN is_VBZ negative_JJ ,_, the_DT interaction_NN is_VBZ significantly_RB antagonistic_JJ ._SENT Agreement_NN between_IN the_DT FIC_JJ index_NN and_CC the_DT response_NN surface_NN approach_NN ._SENT |_SYM The_DT interactions_NNS found_VBN by_IN the_DT FIC_JJ index_NN were_VBD compared_VBN with_IN those_DT found_VBN by_IN the_DT response_NN surface_NN approach_NN for_IN both_CC the_DT 5FC-AB_NP and_CC 5FC-FCZ_NP combinations_NNS ._SENT The_DT percentage_NN agreement_NN between_IN both_DT methods_NNS for_IN both_DT combinations_NNS was_VBD determined_VBN ._SENT All_DT yeast_NN isolates_NNS grew_VBD well_RB after_IN 48_CD h_NN of_IN incubation_NN at_IN 35C_JJ ._SENT In_IN each_DT batch_NN of_IN broth_NN microdilution_NN tests_NNS ,_, the_DT MICs_NP for_IN the_DT quality_NN control_NN strains_NNS were_VBD within_IN the_DT reference_NN ranges_NNS ._SENT MIC_JJ data_NNS ._SENT |_SYM Table_NP shows_VBZ the_DT MICs_NP of_IN 5FC_NP ,_, AB_NP ,_, and_CC FCZ_NP for_IN the_DT 35_CD yeast_NN isolates_NNS ,_, using_VBG the_DT MIC-0_NP for_IN AB_NP and_CC the_DT MIC-1_NP for_IN 5FC_NP and_CC FCZ_NP ._SENT FIC_JJ index_NN ._SENT |_SYM Table_NP shows_VBZ the_DT FIC_JJ indices_NN of_IN the_DT 35_CD yeast_NN isolates_NNS for_IN the_DT 5FC-AB_NP and_CC 5FC-FCZ_NP combinations_NNS determined_VBN by_IN a_DT broth_NN microdilution_NN checkerboard_NN method_NN ,_, together_RB with_IN the_DT results_NNS obtained_VBN by_IN the_DT response_NN surface_NN approach_NN (_( see_VB below_IN )_) ._SENT 5FC-AB_JJ combination_NN ._SENT |_SYM For_IN the_DT 5FC-AB_JJ combination_NN much_JJ variation_NN was_VBD found_VBN between_IN the_DT Candida_NP isolates_VBZ ,_, both_CC between_IN species_NNS as_IN well_RB as_RB within_IN species_NNS ._SENT Synergism_NN was_VBD observed_VBN for_IN four_CD C._NP albicans_NNS isolates_NNS ,_, and_CC antagonism_NN was_VBD observed_VBN for_IN five_CD C._NP albicans_NNS isolates_NNS ,_, with_IN the_DT FIC_JJ index_NN ranging_VBG from_IN 0.65_CD to_TO 2.12_CD and_CC a_DT median_JJ FIC_NP (_( FIC50_NP )_) of_IN 1.33_CD ._SENT For_IN C._NP krusei_NP synergism_NN was_VBD observed_VBN for_IN three_CD isolates_NNS ,_, and_CC antagonism_NN was_VBD observed_VBN for_IN six_CD isolates_NNS ,_, with_IN the_DT FIC_JJ index_NN ranging_VBG from_IN 0.50_CD to_TO 2.31_CD and_CC a_DT FIC50_NP of_IN 1.17_CD ._SENT For_IN C._NP glabrata_NP synergism_NN was_VBD observed_VBN for_IN six_CD isolates_NNS and_CC antagonism_NN was_VBD observed_VBN for_IN three_CD isolates_NNS ,_, with_IN the_DT FIC_JJ index_NN ranging_VBG from_IN 0.57_CD to_TO 1.89_CD and_CC a_DT FIC50_NP of_IN 0.92_CD ._SENT Thus_RB ,_, the_DT FIC50_NP for_IN all_DT 27_CD Candida_NP isolates_NNS indicate_VBP that_IN ,_, overall_RB ,_, there_EX was_VBD slight_JJ in_IN vitro_NN antagonism_NN for_IN the_DT 5FC-AB_JJ combination_NN (_( FIC50_NP =_SYM 1.14_CD )_) ,_, but_CC this_DT combination_NN appeared_VBD to_TO be_VB synergistic_JJ for_IN some_DT isolates_NNS ._SENT In_IN vitro_NN antagonism_NN was_VBD observed_VBN for_IN all_DT eight_CD C._NP neoformans_NNS isolates_NNS ,_, with_IN the_DT FIC_JJ index_NN ranging_VBG from_IN 1.05_CD to_TO 3.50_CD and_CC a_DT FIC50_NP of_IN 1.83_CD ._SENT 5FC-FCZ_NP combination_NN ._SENT |_SYM For_IN the_DT 5FC-FCZ_NP combination_NN ,_, synergism_NN was_VBD observed_VBN for_IN five_CD C._NP albicans_NNS isolates_NNS and_CC antagonism_NN for_IN four_CD C._NP albicans_NNS isolates_NNS ,_, with_IN the_DT FIC_JJ index_NN ranging_VBG from_IN 0.07_CD to_TO 9.50_CD and_CC a_DT FIC50_NP of_IN 0.29_CD ._SENT For_IN C._NP krusei_NP synergism_NN was_VBD observed_VBN for_IN one_CD isolate_NN and_CC antagonism_NN was_VBD observed_VBN for_IN eight_CD isolates_NNS ,_, with_IN the_DT FIC_JJ index_NN ranging_VBG from_IN 0.31_CD to_TO 2.88_CD and_CC a_DT FIC50_NP of_IN 2.17_CD ._SENT For_IN C._NP glabrata_NP antagonism_NN was_VBD observed_VBN for_IN all_DT nine_CD isolates_NNS ,_, with_IN the_DT FIC_JJ index_NN ranging_VBG from_IN 1.50_CD to_TO 16.50_CD and_CC a_DT FIC50_NP of_IN 5.04_CD ._SENT Importantly_RB ,_, for_IN all_DT C._NP glabrata_NN isolates_VBZ the_DT mean_JJ MIC_NN of_IN the_DT triplicates_NNS of_IN FCZ_NP increased_VBD from_IN 64_CD to_TO >128_JJ mug/ml_NN when_WRB used_VBN in_IN combination_NN with_IN 5FC_NP ._SENT In_IN general_NN ,_, the_DT 5FC-FCZ_NP combination_NN was_VBD antagonistic_JJ against_IN Candida_NP species_NNS (_( FIC50_NP =_SYM 2.17_CD )_) ,_, although_IN marked_JJ synergism_NN was_VBD observed_VBN for_IN some_DT isolates_NNS (_( FIC_JJ index_NN down_RB to_TO 0.07_CD )_) ._SENT Interestingly_RB ,_, the_DT MIC_NP of_IN 5FC_NP was_VBD lowered_VBN by_IN at_IN least_JJS 1_CD dilution_NN step_NN when_WRB combined_VBN with_IN FCZ_NP for_IN all_DT Candida_NP isolates_VBZ ._SENT Synergism_NN was_VBD observed_VBN for_IN one_CD C._NP neoformans_NNS isolate_VBP ,_, and_CC antagonism_NN was_VBD observed_VBN for_IN seven_CD C._NP neoformans_NNS isolates_NNS ,_, with_IN the_DT FIC_JJ index_NN ranging_VBG from_IN 0.63_CD to_TO 9.02_CD and_CC a_DT FIC50_NP of_IN 1.73_CD ._SENT Response_NN surface_NN approach_NN ._SENT |_SYM Table_NP also_RB shows_VBZ the_DT interaction_NN coefficient_NN (_( ICalpha_NP )_) of_IN the_DT 35_CD yeast_NN isolates_NNS for_IN 5FC-AB_NP and_CC 5FC-FCZ_NP as_RB determined_VBD by_IN the_DT response_NN surface_NN approach_NN ._SENT Model_NN fits_NNS were_VBD performed_VBN for_IN each_DT isolate_NN and_CC drug_NN combination_NN ._SENT An_DT example_NN is_VBZ shown_VBN in_IN Fig._NN ._SENT 5FC-AB_JJ combination_NN ._SENT |_SYM For_IN the_DT 5FC-AB_JJ combination_NN much_JJ variation_NN was_VBD found_VBN between_IN the_DT yeast_NN isolates_VBZ ._SENT Synergism_NN was_VBD observed_VBN for_IN four_CD C._NP albicans_NNS isolates_NNS ,_, and_CC antagonism_NN for_IN five_CD C._NP albicans_NNS isolates_NNS ,_, with_IN the_DT ICalpha_NP ranging_VBG from_IN -0.136_CD to_TO 0.892_CD and_CC a_DT median_JJ ICalpha_NP (_( ICalpha50_NP )_) of_IN -0.071_CD ._SENT For_IN C._NP krusei_NP synergism_NN was_VBD observed_VBN for_IN seven_CD isolates_NNS and_CC antagonism_NN was_VBD observed_VBN for_IN two_CD isolates_NNS ,_, with_IN the_DT ICalpha_NP ranging_VBG from_IN -0.286_CD to_TO 0.996_CD and_CC an_DT ICalpha50_NP of_IN 0.255_CD ._SENT For_IN C._NP glabrata_NP synergism_NN was_VBD observed_VBN for_IN three_CD isolates_NNS and_CC antagonism_NN was_VBD observed_VBN for_IN six_CD isolates_NNS ,_, with_IN the_DT ICalpha_NP ranging_VBG from_IN -0.164_CD to_TO 1.239_CD and_CC an_DT ICalpha50_NP of_IN -0.077_CD ._SENT The_DT ICalpha50_NP for_IN all_DT 27_CD Candida_NP isolates_NNS indicated_VBD slight_JJ synergism_NN for_IN the_DT 5FC-AB_JJ combination_NN (_( ICalpha50_NP =_SYM 0.015_CD )_) ._SENT Synergism_NN was_VBD observed_VBN for_IN six_CD C._NP neoformans_NNS isolates_NNS ,_, and_CC antagonism_NN was_VBD observed_VBN for_IN two_CD C._NP neoformans_NNS isolates_NNS ,_, with_IN the_DT ICalpha_NP ranging_VBG from_IN -0.143_CD to_TO 0.896_CD and_CC an_DT ICalpha50_NP of_IN 0.162_CD ._SENT 5FC-FCZ_NP combination_NN ._SENT |_SYM For_IN the_DT 5FC-FCZ_NP combination_NN synergism_NN was_VBD observed_VBN for_IN six_CD of_IN the_DT C._NP albicans_NNS isolates_NNS and_CC antagonism_NN was_VBD observed_VBN for_IN three_CD of_IN the_DT C._NP albicans_NNS isolates_NNS ,_, with_IN the_DT ICalpha_NP ranging_VBG from_IN -0.187_CD to_TO 30.212_CD and_CC an_DT ICalpha50_NP of_IN 6.140_CD ._SENT For_IN C._NP krusei_NP synergism_NN was_VBD observed_VBN for_IN one_CD isolate_NN and_CC antagonism_NN was_VBD observed_VBN for_IN eight_CD isolates_NNS ,_, with_IN the_DT ICalpha_NP ranging_VBG from_IN -0.635_CD to_TO 0.527_CD and_CC an_DT ICalpha50_NP of_IN -0.241_CD ._SENT For_IN C._NP glabrata_NP antagonism_NN was_VBD observed_VBN for_IN all_DT nine_CD isolates_NNS ,_, with_IN the_DT ICalpha_NP ranging_VBG from_IN -0.643_CD to_TO -0.036_CD and_CC an_DT ICalpha50_NP of_IN -0.200_CD ._SENT In_IN general_NN ,_, the_DT 5FC-FCZ_NP combination_NN was_VBD antagonistic_JJ against_IN Candida_NP species_NNS (_( ICalpha50_NP =_SYM -0.180_CD )_) but_CC highly_RB synergistic_JJ in_IN some_DT isolates_NNS (_( ICalpha_NP up_RB to_TO 30.212_CD )_) ._SENT Synergism_NN was_VBD observed_VBN for_IN three_CD C._NP neoformans_NNS isolates_NNS ,_, and_CC antagonism_NN was_VBD observed_VBN for_IN five_CD C._NP neoformans_NNS isolates_NNS ,_, with_IN the_DT ICalpha_NP ranging_VBG from_IN -0.264_CD to_TO 13.241_CD and_CC an_DT ICalpha50_NP of_IN -0.024_CD ._SENT Agreement_NN between_IN the_DT FIC_JJ index_NN and_CC the_DT response_NN surface_NN approach_NN ._SENT |_SYM The_DT percentage_NN of_IN agreement_NN in_IN the_DT interpretation_NN of_IN the_DT FIC_JJ index_NN results_NNS and_CC the_DT response_NN surface_NN approach_NN results_NNS was_VBD 91_CD %_NN for_IN the_DT 5FC-FCZ_NP combination_NN ._SENT For_IN the_DT 5FC-AB_JJ combination_NN the_DT agreement_NN between_IN both_DT methods_NNS was_VBD much_RB lower_JJR ,_, namely_RB ,_, 40_CD %_NN :_: only_RB 14_CD of_IN the_DT 35_CD yeast_NN isolates_NNS gave_VBD the_DT same_JJ results_NNS when_WRB determined_VBN by_IN both_DT methods_NNS ._SENT Thus_RB ,_, there_EX is_VBZ a_DT discrepancy_NN between_IN the_DT results_NNS of_IN the_DT two_CD methods_NNS ._SENT The_DT effect_NN of_IN several_JJ variables_NNS on_IN the_DT level_NN of_IN agreement_NN ._SENT |_SYM Because_IN we_PP found_VBD a_DT low_JJ level_NN of_IN agreement_NN between_IN both_DT methods_NNS for_IN the_DT 5FC-AB_JJ combination_NN ,_, we_PP analyzed_VBD the_DT effect_NN of_IN several_JJ variables_NNS on_IN the_DT level_NN of_IN agreement_NN ._SENT Interpretation_NN of_IN FIC_JJ index_NN ._SENT |_SYM Different_JJ definitions_NNS for_IN the_DT interpretation_NN of_IN the_DT FIC_JJ index_NN can_MD be_VB found_VBN in_IN the_DT literature_NN ._SENT Figure_NN shows_VBZ the_DT percentages_NNS of_IN synergism_NN ,_, addition_NN ,_, indifference_NN ,_, and_CC antagonism_NN for_IN 5FC-AB_NP and_CC 5FC-FCZ_NP ,_, determined_VBN by_IN the_DT different_JJ definitions_NNS for_IN the_DT interpretation_NN of_IN the_DT FIC_JJ index_NN given_VBN in_IN Table_NP ._SENT As_RB can_MD be_VB observed_VBN from_IN the_DT figures_NNS ,_, large_JJ discrepancies_NNS occur_VBP ._SENT For_IN instance_NN ,_, for_IN the_DT 5FC-FCZ_NP combination_NN synergism_NN was_VBD found_VBN between_IN 17_CD and_CC 20_CD %_NN of_IN isolates_NNS ,_, while_IN antagonism_NN was_VBD found_VBN between_IN 26_CD %_NN (_( following_VBG the_DT definition_NN of_IN Walsh_NP et_FW al._FW or_CC White_NP et_FW al._FW )_) to_TO 80_CD %_NN (_( following_VBG the_DT definition_NN of_IN Berenbaum_NP or_CC Eliopoulos_NP )_) of_IN isolates_NNS ._SENT Table_NN shows_VBZ the_DT percentage_NN of_IN agreement_NN between_IN the_DT interpretation_NN of_IN the_DT FIC_JJ index_NN results_NNS and_CC the_DT response_NN surface_NN approach_NN for_IN both_CC the_DT 5FC-AB_NP and_CC 5FC-FCZ_NP combination_NN depending_VBG on_IN the_DT definition_NN chosen_VBN ._SENT As_RB can_MD be_VB observed_VBN ,_, the_DT level_NN of_IN agreement_NN varied_VBN between_IN 0_CD and_CC 40_CD %_NN for_IN the_DT 5FC-AB_JJ combination_NN and_CC between_IN 43_CD %_NN and_CC 91_CD %_NN for_IN the_DT 5FC-FCZ_NP combination_NN ._SENT Dependence_NN of_IN FIC_NP on_IN MIC_NP end_NN point_NN ._SENT |_SYM The_DT level_NN of_IN agreement_NN between_IN the_DT interpretation_NN of_IN the_DT FIC_JJ index_NN results_NNS and_CC the_DT response_NN surface_NN approach_NN results_NNS for_IN the_DT 5FC-AB_JJ combination_NN was_VBD determined_VBN with_IN regard_NN to_TO the_DT MIC_NP and_CC the_DT degree_NN of_IN inhibition_NN used_VBN in_IN the_DT combination_NN ._SENT The_DT level_NN of_IN agreement_NN varied_VBN between_IN 43_CD %_NN (_( 15_CD of_IN 35_CD isolates_NNS )_) (_( MIC-0_NP for_IN AB_NP ,_, MIC-1_NP for_IN 5FC_NP ,_, and_CC 100_CD %_NN inhibition_NN for_IN the_DT combination_NN )_) and_CC 60_CD %_NN (_( 21_CD of_IN 35_CD isolates_NNS )_) (_( MIC-0_NP for_IN AB_NP and_CC 5FC_NP and_CC 100_CD %_NN inhibition_NN for_IN the_DT combination_NN ;_: MIC-0_NP for_IN AB_NP ,_, MIC-1_NP for_IN 5FC_NP and_CC 80_CD %_NN inhibition_NN for_IN the_DT combination_NN ;_: and_CC MIC-1_NP for_IN AB_NP and_CC 5FC_NP and_CC 80_CD %_NN inhibition_NN for_IN the_DT combination_NN )_) ._SENT FIG._NN 1_CD ._SENT |_SYM Effect_JJ surface_NN response_NN of_IN one_CD of_IN the_DT triplicates_NNS of_IN Candida_NP krusei_NP 1_25_NP for_IN 5FC_NP in_IN combination_NN with_IN AB_NP ._SENT Effect_NN surface_NN response_NN of_IN one_CD of_IN the_DT triplicates_NNS of_IN Candida_NP krusei_NP 1_25_NP for_IN 5FC_NP in_IN combination_NN with_IN AB_NP ._SENT The_DT ICalpha_NP (_( 95_CD %_NN confidence_NN interval_NN )_) of_IN this_DT isolate_NN was_VBD 1.196_CD (_( 0.853_CD to_TO 1.676_CD )_) ,_, indicating_VBG synergism_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Interactions_NP found_VBN by_IN using_VBG different_JJ definitions_NNS for_IN the_DT FIC_JJ index_NN for_IN the_DT 5FC-AB_NN (_( a_DT )_) and_CC for_IN the_DT 5FC-FCZ_NP (_( b_LS )_) combinations_NNS ._SENT Interactions_NNS found_VBD by_IN using_VBG different_JJ definitions_NNS for_IN the_DT FIC_JJ index_NN for_IN the_DT 5FC-AB_NN (_( a_DT )_) and_CC for_IN the_DT 5FC-FCZ_NP (_( b_LS )_) combinations_NNS ._SENT TABLE_NN 1_CD |_SYM MICs_NP of_IN 5FC_NP ,_, AB_NP ,_, and_CC FCZ_NP for_IN 35_CD yeast_NN isolates_VBZ TABLE_NP 2_CD |_SYM In_IN vitro_NN interaction_NN between_IN 5FC_NP and_CC AB_NP or_CC FCZ_NP for_IN 35_CD yeast_NN isolates_VBZ as_RB determined_VBN by_IN FIC_JJ index_NN and_CC ICalpha_NP TABLE_NP 3_CD |_SYM Definitions_NNS for_IN interpretation_NN of_IN the_DT FIC_NP index_NN TABLE_NP 4_CD |_SYM Level_NP of_IN agreement_NN between_IN the_DT interpretation_NN of_IN the_DT FIC_JJ index_NN results_NNS and_CC the_DT response_NN surface_NN approach_NN results_NNS In_IN the_DT present_JJ study_NN we_PP determined_VBD the_DT interaction_NN between_IN 5FC_NP and_CC AB_NP or_CC FCZ_NP and_CC showed_VBD that_IN the_DT interaction_NN is_VBZ largely_RB dependent_JJ on_IN the_DT tested_VBN isolate_NN ._SENT We_PP also_RB demonstrate_VBP that_IN the_DT use_NN of_IN the_DT FIC_JJ index_NN in_IN synergy_NN studies_NNS of_IN antifungal_JJ agents_NNS has_VBZ some_DT important_JJ disadvantages_NNS in_IN that_WDT the_DT results_NNS can_MD be_VB interpreted_VBN in_IN different_JJ ways_NNS ._SENT First_JJ of_IN all_PDT there_EX are_VBP different_JJ definitions_NNS described_VBN in_IN the_DT literature_NN for_IN the_DT interpretation_NN of_IN the_DT FIC_JJ index_NN ._SENT There_EX is_VBZ no_DT consensus_NN on_IN which_WDT definition_NN to_TO use_VB in_IN synergy_NN studies_NNS ._SENT In_IN this_DT study_NN we_PP compared_VBD the_DT interactions_NNS found_VBN by_IN these_DT different_JJ definitions_NNS for_IN both_CC the_DT combination_NN of_IN 5FC_NP with_IN AB_NP and_CC that_IN of_IN 5FC_NN with_IN FCZ_NP ._SENT Large_JJ discrepancies_NNS were_VBD found_VBN ,_, depending_VBG on_IN the_DT definitions_NNS used_VBD ._SENT For_IN example_NN ,_, synergism_NN was_VBD found_VBN between_IN 17_CD and_CC 20_CD %_NN of_IN isolates_NNS ,_, while_IN antagonism_NN varied_VBN from_IN 26_CD to_TO 80_CD %_NN of_IN the_DT isolates_NNS for_IN the_DT combination_NN of_IN 5FC_NP with_IN FCZ_NP ._SENT Not_RB only_RB the_DT definitions_NNS but_CC also_RB the_DT lack_NN of_IN a_DT statistical_JJ criterion_NN to_TO define_VB these_DT interactions_NNS contribute_VBP to_TO these_DT varying_VBG results_NNS ._SENT A_DT second_JJ disadvantage_NN is_VBZ that_IN it_PP is_VBZ not_RB clear_JJ at_IN which_WDT MIC_JJ end_NN point_NN the_DT combination_NN should_MD be_VB read_VBN ._SENT This_DT question_NN is_VBZ particularly_RB important_JJ when_WRB a_DT combination_NN of_IN drugs_NNS with_IN different_JJ MIC_JJ end_NN points_NNS is_VBZ used_VBN ._SENT In_IN another_DT study_NN we_PP determined_VBD the_DT interaction_NN between_IN AB_NP and_CC itraconazole_NN against_IN 15_CD Aspergillus_NP fumigatus_NN isolates_NNS ._SENT Depending_VBG on_IN the_DT chosen_JJ MIC_JJ end_NN point_NN the_DT mean_JJ FIC_JJ index_NN varied_VBN between_IN 1.016_CD and_CC 2.077_CD for_IN 10_CD itraconazole-susceptible_JJ isolates_NNS or_CC between_IN 0.308_CD and_CC 1.767_CD for_IN five_CD itraconazole-resistant_JJ isolates_NNS ._SENT Thus_RB ,_, the_DT interaction_NN found_VBD by_IN the_DT FIC_JJ index_NN depends_VBZ not_RB only_RB on_IN the_DT chosen_VBN combination_NN but_CC also_RB on_IN the_DT choice_NN of_IN interpretation_NN of_IN the_DT FIC_JJ index_NN and_CC ,_, for_IN some_DT drug_NN combinations_NNS ,_, on_IN the_DT choice_NN of_IN MIC_JJ end_NN point_NN ._SENT From_IN this_DT ,_, we_PP conclude_VBP that_IN the_DT FIC_JJ index_NN is_VBZ not_RB an_DT optimal_JJ instrument_NN to_TO describe_VB interactions_NNS between_IN antifungal_JJ agents_NNS ._SENT To_TO overcome_VB these_DT problems_NNS a_DT response_NN surface_NN approach_NN as_IN described_VBN by_IN Greco_NP et_FW al._FW can_MD be_VB used_VBN to_TO determine_VB the_DT interaction_NN between_IN antifungal_JJ agents_NNS ._SENT The_DT use_NN of_IN a_DT model_NN fit_NN at_IN least_JJS allows_VBZ an_DT objective_JJ statistical_JJ criterion_NN and_CC it_PP makes_VBZ an_DT arbitrarily_RB chosen_VBN end_NN point_NN unnecessary_JJ ._SENT Fitting_VBG of_IN a_DT model_NN to_TO the_DT whole_JJ data_NNS surface_VBP not_RB only_RB allows_VBZ the_DT optimal_JJ use_NN of_IN information_NN in_IN the_DT data_NNS but_CC also_RB allows_VBZ the_DT determination_NN of_IN error_NN estimates_NNS of_IN the_DT interaction_NN coefficient_NN ,_, thereby_RB indicating_VBG whether_IN the_DT interaction_NN is_VBZ significant_JJ or_CC not_RB ._SENT Since_IN the_DT effect_NN of_IN drug_NN interaction_NN may_MD vary_VB between_IN individual_NN isolates_VBZ this_DT is_VBZ an_DT important_JJ feature_NN ._SENT For_IN the_DT FIC_JJ index_NN a_DT statistical_JJ approach_NN was_VBD described_VBN earlier_RBR by_IN Drusano_NP ,_, but_CC because_IN of_IN its_PP$ complexity_NN it_PP is_VBZ generally_RB not_RB used_VBN ._SENT Alternatively_RB ,_, not_RB only_RB does_VBZ the_DT interaction_NN coefficient_NN indicate_VBP whether_IN there_EX is_VBZ significance_NN or_CC not_RB ,_, but_CC the_DT value_NN found_VBD also_RB gives_VBZ an_DT indication_NN of_IN the_DT degree_NN of_IN interaction_NN ._SENT This_DT approach_NN was_VBD used_VBN successfully_RB in_IN synergy_NN studies_NNS of_IN antivirals_NNS ._SENT In_IN fitting_VBG the_DT surface_NN response_NN model_NN to_TO the_DT data_NNS ,_, two_CD approaches_NNS can_MD be_VB taken_VBN ._SENT The_DT first_JJ one_CD ,_, and_CC in_IN most_JJS cases_NNS the_DT approach_NN of_IN preference_NN ,_, would_MD be_VB to_TO use_VB an_DT inverse_JJ variance_NN weighting_NN scheme_NN ._SENT In_IN such_PDT a_DT circumstance_NN ,_, one_PP would_MD take_VB the_DT three_CD determinations_NNS for_IN each_DT strain_NN and_CC calculate_VB the_DT mean_JJ and_CC standard_JJ deviation_NN of_IN the_DT response_NN for_IN each_DT well_NN ._SENT The_DT mean_NN would_MD be_VB the_DT observation_NN ._SENT The_DT variance_NN would_MD be_VB calculated_VBN from_IN the_DT standard_JJ deviation_NN ,_, and_CC the_DT inverse_NN of_IN the_DT observation_NN variance_NN would_MD be_VB taken_VBN as_IN the_DT weight_NN ._SENT We_PP used_VBD this_DT approach_NN initially_RB ,_, but_CC we_PP encountered_VBD the_DT problem_NN that_IN the_DT intra-assay_NN variance_NN was_VBD much_RB smaller_JJR than_IN the_DT interassay_NN variance_NN ._SENT Thus_RB ,_, although_IN the_DT surface_NN fit_NN would_MD be_VB very_RB reasonable_JJ for_IN each_DT of_IN the_DT three_CD experiments_NNS ,_, using_VBG the_DT inverse_JJ variance_NN for_IN each_DT measurement_NN in_IN each_DT well_NN did_VBD not_RB always_RB work_VB out_RP ._SENT We_PP therefore_RB chose_VBD to_TO fit_VB the_DT surface_NN to_TO the_DT results_NNS of_IN the_DT individual_JJ experiments_NNS ._SENT Although_IN this_DT assumes_VBZ homoscedasticity_NN ,_, the_DT results_NNS of_IN the_DT model_NN fit_NN suggest_VBP this_DT to_TO be_VB fairly_RB reasonable_JJ ._SENT To_TO determine_VB the_DT relationship_NN between_IN the_DT two_CD methods_NNS ,_, the_DT level_NN of_IN agreement_NN was_VBD determined_VBN for_IN the_DT various_JJ combinations_NNS ._SENT For_IN the_DT combination_NN of_IN 5FC_NP with_IN FCZ_NP the_DT level_NN of_IN agreement_NN between_IN the_DT interpretation_NN of_IN the_DT FIC_JJ index_NN results_NNS and_CC the_DT response_NN surface_NN approach_NN results_NNS was_VBD very_RB high_JJ (_( 91_CD %_NN )_) ._SENT In_IN contrast_NN ,_, the_DT level_NN of_IN agreement_NN for_IN the_DT combination_NN of_IN 5FC_NP with_IN AB_NP was_VBD very_RB low_JJ (_( 40_CD %_NN )_) ._SENT There_EX may_MD be_VB two_CD explanations_NNS for_IN the_DT low_JJ level_NN of_IN agreement_NN of_IN this_DT latter_JJ combination_NN ,_, namely_RB ,_, the_DT chosen_VBN definition_NN for_IN the_DT interpretation_NN of_IN the_DT FIC_JJ index_NN and_CC ,_, moreover_RB ,_, the_DT chosen_JJ MIC_JJ end_NN point_NN (_( data_NNS in_IN Results_NNS )_) ._SENT This_DT is_VBZ substantiated_VBN by_IN the_DT fact_NN that_IN for_IN the_DT combination_NN of_IN 5FC_NP with_IN FCZ_NP the_DT level_NN of_IN agreement_NN was_VBD relatively_RB high_JJ ._SENT MICs_NNS of_IN both_DT 5FC_NP and_CC FCZ_NP are_VBP read_VBN at_IN the_DT same_JJ end_NN point_NN ;_: thus_RB ,_, there_EX is_VBZ no_DT difficulty_NN in_IN the_DT choice_NN of_IN the_DT end_NN point_NN when_WRB calculating_VBG the_DT FIC_JJ index_NN ._SENT In_IN contrast_NN ,_, for_IN the_DT combination_NN of_IN 5FC_NP with_IN AB_NP there_EX is_VBZ a_DT difference_NN in_IN the_DT reading_VBG end_NN points_NNS (_( MIC_NP )_) ._SENT The_DT results_NNS show_VBP that_IN the_DT choice_NN of_IN end_NN point_NN much_RB more_RBR influences_VBZ the_DT level_NN of_IN agreement_NN (_( data_NNS in_IN Results_NNS )_) than_IN the_DT definition_NN itself_PP ._SENT The_DT use_NN of_IN the_DT response_NN surface_NN approach_NN precludes_VBZ all_PDT these_DT interpretation_NN problems_NNS ,_, by_IN estimating_VBG parameters_NNS independent_JJ of_IN a_DT chosen_VBN end_NN point_NN ._SENT The_DT clinically_RB most_RBS used_VBN combination_NN of_IN antifungal_JJ drugs_NNS is_VBZ 5FC_JJ with_IN AB_NP for_IN Candida_NP and_CC Cryptococcus_NP infections_NNS ._SENT The_DT superiority_NN of_IN the_DT combination_NN over_IN either_DT drug_NN alone_RB in_IN Cryptococcus_NP infections_NNS has_VBZ been_VBN described_VBN in_IN both_DT case_NN series_NN and_CC randomized_VBN trials_NNS ._SENT Currently_RB no_RB randomized_VBN trials_NNS have_VBP been_VBN conducted_VBN to_TO determine_VB whether_IN combination_NN therapy_NN of_IN 5FC_NP with_IN AB_NP is_VBZ superior_JJ to_TO monotherapy_NN for_IN invasive_JJ Candida_NP infections_NNS ._SENT However_RB ,_, combination_NN therapy_NN is_VBZ recommended_VBN in_IN several_JJ conditions_NNS of_IN invasive_JJ candidiasis_NN ,_, such_JJ as_IN meningitis_NN ,_, endophthalmitis_NN ,_, endocarditis_NN and_CC peritonitis_NN ._SENT Furthermore_RB ,_, it_PP has_VBZ been_VBN shown_VBN that_IN human_JJ immunodeficiency_NN virus-infected_JJ patients_NNS with_IN cryptococcal_JJ meningitis_NN could_MD possibly_RB benefit_VB from_IN the_DT combination_NN of_IN 5FC_NP with_IN FCZ_NP ._SENT However_RB ,_, these_DT studies_NNS provide_VBP no_DT data_NNS on_IN the_DT interactions_NNS of_IN the_DT two_CD combinations_NNS in_IN vitro_NN ._SENT The_DT combination_NN of_IN 5FC_NP with_IN AB_NP showed_VBD synergism_NN or_CC indifference_NN against_IN C._NP neoformans_NP and_CC Candida_NP strains_NNS ._SENT The_DT combination_NN of_IN 5FC_NP with_IN FCZ_NP showed_VBD synergism_NN ,_, indifference_NN or_CC addition_NN ,_, but_CC no_DT antagonism_NN against_IN C._NP neoformans_NNS strains_NNS ._SENT In_IN this_DT study_NN we_PP found_VBD that_IN the_DT in_IN vitro_NN interaction_NN of_IN the_DT combination_NN of_IN 5FC_NP with_IN AB_NP demonstrated_VBD variable_JJ results_NNS depending_VBG on_IN the_DT tested_VBN Candida_NP isolate_NN ._SENT The_DT combination_NN of_IN 5FC_NP with_IN FCZ_NP was_VBD generally_RB antagonistic_JJ ,_, but_CC for_IN some_DT Candida_NP isolates_NNS synergism_NN was_VBD found_VBN ._SENT The_DT in_IN vitro_NP inhibitory_JJ activity_NN of_IN 5FC_NP was_VBD greatly_RB enhanced_VBN by_IN the_DT addition_NN of_IN FCZ_NP ._SENT The_DT MICs_NP of_IN 5FC_NP for_IN Candida_NP were_VBD decreased_VBN by_IN at_IN least_JJS 1_CD dilution_NN step_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT addition_NN of_IN 5FC_NP did_VBD not_RB greatly_RB enhance_VB the_DT in_IN vitro_NN activity_NN of_IN FCZ_NP ._SENT For_IN the_DT C._NP glabrata_NN strains_VBZ the_DT mean_JJ MIC_NN of_IN the_DT triplicates_NNS of_IN FCZ_NP even_RB increased_VBD from_IN 64_CD mug/ml_NN when_WRB used_VBN alone_RB to_TO >128_JJ mug/ml_NN when_WRB combined_VBN with_IN 5FC_NP ._SENT The_DT interaction_NN found_VBD for_IN the_DT in_IN vitro_NN combination_NN of_IN 5FC_NP with_IN AB_NP or_CC FCZ_NP against_IN C._NP neoformans_NNS varied_VBD ,_, depending_VBG on_IN both_CC the_DT tested_VBN isolate_NN and_CC the_DT used_VBN method_NN (_( FIC_JJ index_NN or_CC response_NN surface_NN approach_NN )_) ._SENT A_DT next_JJ step_NN would_MD be_VB to_TO determine_VB whether_IN differences_NNS in_IN clinical_JJ outcome_NN (_( responders_NNS versus_CC nonresponders_NNS of_IN therapy_NN )_) could_MD be_VB explained_VBN using_VBG this_DT approach_NN of_IN interaction_NN studies_NNS ._SENT Our_PP$ results_NNS do_VBP not_RB concur_VB completely_RB with_IN previous_JJ in_IN vitro_NN findings_NNS ._SENT This_DT may_MD mainly_RB be_VB due_JJ to_TO the_DT fact_NN that_IN different_JJ methods_NNS (_( broth_NN macro-_NN and_CC microdilution_NN )_) ,_, different_JJ MIC_JJ end_NN points_NNS and_CC different_JJ methods_NNS of_IN interpretation_NN of_IN the_DT results_NNS were_VBD used_VBN and_CC possibly_RB also_RB that_IN different_JJ fungal_JJ strains_NNS were_VBD tested_VBN ._SENT In_IN the_DT light_NN of_IN these_DT differences_NNS ,_, it_PP is_VBZ necessary_JJ to_TO develop_VB a_DT standard_JJ methodology_NN to_TO determine_VB in_IN vitro_NN antifungal_JJ interactions_NNS ._SENT The_DT response_NN surface_NN approach_NN would_MD be_VB a_DT good_JJ alternative_NN ._SENT It_PP has_VBZ to_TO be_VB emphasized_VBN that_IN the_DT results_NNS obtained_VBN in_IN in_IN vitro_NN studies_NNS do_VBP not_RB necessarily_RB correlate_JJ with_IN clinical_JJ outcome_NN ._SENT Although_IN we_PP found_VBD antagonism_NN between_IN 5FC_NP and_CC FCZ_NP for_IN several_JJ strains_NNS ,_, this_DT combination_NN has_VBZ been_VBN found_VBN to_TO be_VB very_RB useful_JJ in_IN treating_VBG people_NNS with_IN cryptococcal_JJ meningitis_NN ._SENT Also_RB AB_NP in_IN combination_NN with_IN 5FC_NN is_VBZ thought_VBN to_TO be_VB useful_JJ in_IN the_DT treatment_NN of_IN various_JJ forms_NNS of_IN candidiasis_NN ._SENT Other_JJ factors_NNS such_JJ as_IN prolonged_JJ therapy_NN and_CC pharmacokinetic_JJ properties_NNS of_IN the_DT drugs_NNS play_VBP an_DT important_JJ role_NN in_IN in_IN vivo_JJ efficacy_NN ._SENT We_PP conclude_VBP that_IN the_DT response_NN surface_NN approach_NN is_VBZ a_DT good_JJ alternative_NN for_IN determining_VBG the_DT interaction_NN between_IN drugs_NNS against_IN yeasts_NNS and_CC has_VBZ considerable_JJ advantages_NNS over_IN conventional_JJ methods_NNS ._SENT 